Vemurafenib

Type: Keyphrase

Name: Vemurafenib

First reported 19 hours ago - Updated 19 hours ago - 1 reports

Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma

There have been significant advances in the treatment of malignant melanoma with the U.S. Food and Drug Administration approval of two drugs in 2011, the first drugs approved in 13 years. The developments of immune checkpoint modulation via cytotoxic ... [Published The Oncologist - 19 hours ago]

Entities: Ipilimumab, Vemurafenib, Malignant Melanoma, Mutant

First reported May 23 2013 - Updated May 23 2013 - 1 reports

New figures show 3,000 Scots would have benefited from cancer fund

Nearly 3,000 Scottish cancer patients would have benefited had a cancer drugs fund been created in Scotland, new figures obtained by the Scottish Conservatives have revealed.The number of those to have accessed medication not routinely available on the ... [Published Scottish Conservative Party - May 23 2013]

Entities: Cancer, Scottish Conservative Party, Drugs

First reported May 23 2013 - Updated May 23 2013 - 1 reports

Prometheus Laboratories enrolls patients in metastatic melanoma study

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, has announced that PROCLIVITY 01, a multi-center study of Proleukin, or High Dose Interleukin-2, or HD IL-2, plus vemurafenib therapy in patients with BRAF V600 mutation-positive ... [Published Individual.com - May 23 2013]

Entities: Vemurafenib, IL-2, Skin Cancer, Metastatic

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Intermittent Zelboraf Treatment in Patients with Melanoma May Prevent Resistance to the Drug

Categories: Melanoma, News, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma Tumors resistant to Zelboraf® (vemurafenib) in patients with melanoma showed reduced growth after treatment was stopped. What’s more—animal models have shown that drug ... [Published CancerConnect.com - May 22 2013]

Entities: Skin Cancer, Zelboraf, Patient, Tumor

First reported May 22 2013 - Updated May 22 2013 - 1 reports

NHS

NHS chief: ‘OK’ to deny patients lifesaving drugs

SCOTLAND’S medicines chief has insisted it is sometimes "OK to say no" to lifesaving drugs, if they do not come at a fair price for the NHS. Professor Angela Timoney, chairwoman of the Scottish Medicines Consortium (SMC), defended the decision to deny ... [Published The Scotsman - May 22 2013]

Entities: NHS, Drugs, Patient, Scotland

First reported May 18 2013 - Updated May 18 2013 - 1 reports

Keeping Tumors Off Guard: Intermittent Dosing May Prolong Vemurafenib Sensitivity in Melanoma

WASHINGTON—Vemurafenib triggers dramatic regression of BRAF-mutant melanoma in the majority of patients. The response, though, is unfortunately often short-lived, with resistance arising after six to nine months. However, as reported in a study here at ... [Published Oncology Times - May 18 2013]

Entities: Vemurafenib, Skin Cancer, Tumor, Drugs, Patient

First reported May 18 2013 - Updated May 18 2013 - 1 reports

erlotinib

Dermatologic Adverse Events Associated With Targeted Therapies

Novel cancer therapies have brought about unprecedented improvements in survival along with decreased hematopoietic toxicities, when compared with cytotoxic chemotherapy. Therefore, other components of the cancer experience have come forward, such as ... [Published Cancernetwork.com - May 18 2013]

Entities: Exanthema subitum, Vemurafenib, Ipilimumab, erlotinib, Patient

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Advances in the Systemic Treatment of Metastatic Melanoma

ABSTRACT: Prior to 2011, the only commercially available agents commonly used to treat metastatic melanoma—including dacarbazine, temozolomide (Temodar), fotemustine, carboplatin, paclitaxel, and interleukin-2—demonstrated limited efficacy, and no study ... [Published Consultant Live - May 16 2013]

Entities: Ipilimumab, Skin Cancer, Tumor, Patient, Lymphocyte

First reported May 09 2013 - Updated May 09 2013 - 1 reports

Prometheus Laboratories Inc. Launches PROCLIVITY(SM) 01 Clinical Trial of Proleukin® (Aldesleukin for Injection) Plu

/PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announces that PROCLIVITY 01, a multi-center study of Proleukin(®) (High Dose Interleukin-2 (HD IL-2))[1] plus vemurafenib therapy in patients with BRAF( ... [Published NewsBlaze - May 09 2013]

Entities: Vemurafenib, Proleukin, IL-2

First reported May 08 2013 - Updated May 08 2013 - 1 reports

Gossypin Blocks Melanoma Growth in Culture and Xenograft Models

Gossypin, a glucoside occurring in cotton and Hibiscus flowers, has been shown to be a potent drug for the treatment for melanoma, which causes the majority of deaths from skin cancer.Mutation in the BRAF gene (BRAF-V600E) is present in nearly 70% of ... [Published Biotech Daily - May 08 2013]

Entities: Skin Cancer, Kinase, xenograft

First reported May 08 2013 - Updated May 08 2013 - 1 reports

United Kindom pharmaceutical market: Latest market research analysed

Drugmakers and governments will increasingly enter agreements that provide some form of risk- sharing or price protection for new drugs. Since most European governments, including the UK authorities, are focussing on cost containment in the healthcare ... [Published TransWorldNews - May 08 2013]

Entities: National Institute for Health & Clinical Excell..., US Dollar, treatments, Ipilimumab, Zelboraf

First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

Therapeutic combos make inroads in advanced melanoma

WAILEA, HAWAII – "The past 2 years have been a really exciting time for those of us who have spent the last several decades" in the field of melanoma, said Dr. Allan C. Halpern, chief of the dermatology service at Memorial Sloan Kettering Cancer Center, ... [Published Oncology Report - Apr 30 2013]

Entities: Skin Cancer, Vemurafenib, Ipilimumab

Quotes

...resistant to chemotherapy," explains Li, a professor of Biochemistry and Canada Research Chair in Cellular Proteomics and Functional Genomics. "So if we can prevent Numb from being methylated in cancer cells, then we will have the means to sensitize the cell to chemotherapy."

Research identifies a way to make cancer cells more responsive to chemotherapy [Published Brightsurf Science News - May 24 2013]

...marked by significant advances in understanding the key molecular signaling events underlying the pathogenesis of melanoma," explained Dr Lowder. "We now know that the BRAF V600 mutation is found in approximately 50% of melanomas, especially in younger individuals. If, by combining BRAF inhibition with immunotherapy, we could improve the durable complete response rate over that seen with high-dose interleukin-2 alone, it would be viewed as a significant advance in the management of metastatic melanoma."

Prometheus Laboratories enrolls patients in metastatic melanoma study [Published Individual.com - May 23 2013]

...every treatment at every patient, we could make intelligent decisions and say, "this is a therapy that has a high probability of success" and "this is a therapy that for all practical purposes will not be useful" and make treatment decisions on that basis...

Colorectal Cancer Treatments and Therapy Innovations [Published Cancernetwork.com - May 22 2013]

And Mark Flannagan, chief executive of Beating Bowel Cancer added: "All cancer patients want is a level playing field. Their doctors should have the freedom to prescribe the drugs which they feel will benefit their patient."

NHS chief: ‘OK’ to deny patients lifesaving drugs [Published The Scotsman - May 22 2013]

More Content

sort by: Date \| Relevance
Ipilimumab, Vemurafenib, Dabrafenib, and Tramet... [Published The Oncologist - 19 hours ago]
Research identifies a way to make cancer cells ... [Published Brightsurf Science News - May 24 2013]
New figures show 3,000 Scots would have benefit... [Published Scottish Conservative Party - May 23 2013]
Prometheus Laboratories enrolls patients in met... [Published Individual.com - May 23 2013]
Colorectal Cancer Treatments and Therapy Innova... [Published Cancernetwork.com - May 22 2013]
Medical Breakthroughs 2013: Exposing Skin Cancer [Published Hudson Valley Magazine - May 22 2013]
Intermittent Zelboraf Treatment in Patients wit... [Published CancerConnect.com - May 22 2013]
NHS chief: ‘OK’ to deny patients lifesaving drugs [Published The Scotsman - May 22 2013]
Amgen, Inc. Management Presents at UBS Global H... [Published Seeking Alpha - May 21 2013]
Reviving A Foe Of Cancer [Published Medical News Today - May 21 2013]
Skin cancer: Melanoma the facts [Published Mail Online UK - May 19 2013]
Keeping Tumors Off Guard: Intermittent Dosing M... [Published Oncology Times - May 18 2013]
Dermatologic Adverse Events Associated With Tar... [Published Cancernetwork.com - May 18 2013]
Advances in the Systemic Treatment of Metastati... [Published Consultant Live - May 16 2013]
Early Results Robust for New PD-L1 Immunotherap... [Published OncLive - May 16 2013]
Oncothyreon Inc. (ONTY) Reports First Quarter 2... [Published BioSpace - May 10 2013]
Exelixis Issues 1Q 2013 Financial Results [Published Individual.com - May 10 2013]
Exelixis Reports First Quarter 2013 Financial R... [Published Individual.com - May 10 2013]
New Ways to Fight Deadly Melanoma [Published Bottom Line Publications - May 10 2013]
Data from M. Uhrig and Colleagues Advance Knowl... [Published NewsRX - May 10 2013]
Oncothyreon Inc Management Discusses Q1 2013 Re... [Published Seeking Alpha - May 09 2013]
Oncothyreon Reports First Quarter 2013 Financia... [Published Yahoo! Finance - May 09 2013]
Oncothyreon Reports First Quarter 2013 Financia... [Published Individual.com - May 09 2013]
Oncothyreon Reports First Quarter 2013 Financia... [Published TickerTech.com - May 09 2013]
Prometheus Laboratories Inc. Launches PROCLIVIT... [Published NewsBlaze - May 09 2013]
Prometheus Laboratories Inc. Launches PROCLIVIT... [Published PR Newswire: Health - May 09 2013]
Gossypin Blocks Melanoma Growth in Culture and ... [Published Biotech Daily - May 08 2013]
United Kindom pharmaceutical market: Latest mar... [Published TransWorldNews - May 08 2013]
Exelixis Announces First Quarter 2013 Financial... [Published Business Wire - May 07 2013]
Bristol-Myers Has The Future Of Oncology Therapies [Published Seeking Alpha - May 05 2013]

Blogs

sort by: Date \| Relevance
ZELBORAF (Vemurafenib) Tablet, Film Coated [Gen... [Published DailyMed Drug Label Updates for the last seven ... - Apr 16 2013] Updated Date: Apr 16, 2013 EST ...
Overcoming resistance to vemurafenib in metasta... [Published Pharma Strategy Blog - Apr 15 2013] One of the interesting themes for that emerged for me at AACR this year was the amount of effort that… ...
Dr. Stanislaw Burzynski’s cancer “success” stories [Published Science-Based Medicine - Feb 18 2013] The year 2012 was rung out and the year 2013 will be rung in by news that Eric Merola , propagandist for “brave maverick doctor” Stanislaw Burzynski who claims to have developed a cancer treatment far superior to current conventional science- and ...
Human medicines European Public Assessment Repo... [Published Pending EC decisions and European Public Assess ... - Jan 25 2013]
Drug-resistant melanoma tumors shrink when ther... [Published 3quarksdaily - Jan 10 2013] From PhysOrg: Researchers in California and Switzerland have discovered that melanomas that develop resistance to the anti-cancer drug vemurafenib (marketed as Zelboraf), also develop addiction to the drug, an observation that may have important ...

Press Releases

sort by: Date \| Relevance
Prometheus Laboratories Inc. Launches PROCLIVIT... [Published PR Newswire: Health - May 09 2013]
Exelixis Announces First Quarter 2013 Financial... [Published Business Wire - May 07 2013]
Research and Markets: The Complete Guide to Com... [Published Business Wire - May 02 2013]